2176423 Ontario Ltd. Buys 700,000 Shares of Andean Precious Metals Corp. (CVE:APM) Stock

Andean Precious Metals Corp. (CVE:APM) insider 2176423 Ontario Ltd. purchased 700,000 shares of the company’s stock in a transaction on Tuesday, September 24th. The shares were purchased at an average price of C$1.36 per share, for a total transaction of C$952,000.00.

2176423 Ontario Ltd. also recently made the following trade(s):

• On Monday, September 16th, 2176423 Ontario Ltd. acquired 204,600 shares of Andean Precious Metals stock. The stock was purchased at an average price of C$1.14 per share, with a total value of C$233,141.70.

Andean Precious Metals Price Performance

CVE:APM opened at C$1.35 on Friday. The business has a fifty day simple moving average of C$1.07. Andean Precious Metals Corp. has a 1-year low of C$0.53 and a 1-year high of C$1.49. The firm has a market capitalization of C$201.64 million, a price-to-earnings ratio of 3.58 and a beta of 1.13.

Andean Precious Metals (CVE:APM) last released its quarterly earnings data on Tuesday, August 13th. The company reported C$0.08 earnings per share for the quarter, meeting analysts’ consensus estimates of C$0.08. The business had revenue of C$95.47 million during the quarter. Andean Precious Metals had a return on equity of 41.08% and a net margin of 23.75%. Equities research analysts forecast that Andean Precious Metals Corp. will post 0.3801917 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Desjardins upped their target price on Andean Precious Metals from C$1.60 to C$1.70 and gave the company a “buy” rating in a research report on Tuesday, September 3rd.

About Andean Precious Metals

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.